Further validation of the efficacy of mesenchymal stem cell infusions for reducing mortality in COVID-19 patients with ARDS

Recent double-blind, randomized, controlled trials reported that human umbilical cord-derived mesenchymal stem cell (MSC) infusions in COVID-19 patients with acute respiratory distress syndrome (ARDS) could diminish cytokine storm and lung damage. While these outcomes are significant, additional pha...

Descripción completa

Detalles Bibliográficos
Autores principales: Shetty, Ashok K., Shetty, Padmashri A., Zanirati, Gabriele, Jin, Kunlin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8429629/
https://www.ncbi.nlm.nih.gov/pubmed/34504110
http://dx.doi.org/10.1038/s41536-021-00161-z
_version_ 1783750568671444992
author Shetty, Ashok K.
Shetty, Padmashri A.
Zanirati, Gabriele
Jin, Kunlin
author_facet Shetty, Ashok K.
Shetty, Padmashri A.
Zanirati, Gabriele
Jin, Kunlin
author_sort Shetty, Ashok K.
collection PubMed
description Recent double-blind, randomized, controlled trials reported that human umbilical cord-derived mesenchymal stem cell (MSC) infusions in COVID-19 patients with acute respiratory distress syndrome (ARDS) could diminish cytokine storm and lung damage. While these outcomes are significant, additional phase II/III trials are required to validate the efficacy of MSCs to improve the survival of COVID-19 patients with ARDS. Future studies also need to assess the efficacy of MSCs to prevent long COVID.
format Online
Article
Text
id pubmed-8429629
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-84296292021-09-24 Further validation of the efficacy of mesenchymal stem cell infusions for reducing mortality in COVID-19 patients with ARDS Shetty, Ashok K. Shetty, Padmashri A. Zanirati, Gabriele Jin, Kunlin NPJ Regen Med Comment Recent double-blind, randomized, controlled trials reported that human umbilical cord-derived mesenchymal stem cell (MSC) infusions in COVID-19 patients with acute respiratory distress syndrome (ARDS) could diminish cytokine storm and lung damage. While these outcomes are significant, additional phase II/III trials are required to validate the efficacy of MSCs to improve the survival of COVID-19 patients with ARDS. Future studies also need to assess the efficacy of MSCs to prevent long COVID. Nature Publishing Group UK 2021-09-09 /pmc/articles/PMC8429629/ /pubmed/34504110 http://dx.doi.org/10.1038/s41536-021-00161-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Comment
Shetty, Ashok K.
Shetty, Padmashri A.
Zanirati, Gabriele
Jin, Kunlin
Further validation of the efficacy of mesenchymal stem cell infusions for reducing mortality in COVID-19 patients with ARDS
title Further validation of the efficacy of mesenchymal stem cell infusions for reducing mortality in COVID-19 patients with ARDS
title_full Further validation of the efficacy of mesenchymal stem cell infusions for reducing mortality in COVID-19 patients with ARDS
title_fullStr Further validation of the efficacy of mesenchymal stem cell infusions for reducing mortality in COVID-19 patients with ARDS
title_full_unstemmed Further validation of the efficacy of mesenchymal stem cell infusions for reducing mortality in COVID-19 patients with ARDS
title_short Further validation of the efficacy of mesenchymal stem cell infusions for reducing mortality in COVID-19 patients with ARDS
title_sort further validation of the efficacy of mesenchymal stem cell infusions for reducing mortality in covid-19 patients with ards
topic Comment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8429629/
https://www.ncbi.nlm.nih.gov/pubmed/34504110
http://dx.doi.org/10.1038/s41536-021-00161-z
work_keys_str_mv AT shettyashokk furthervalidationoftheefficacyofmesenchymalstemcellinfusionsforreducingmortalityincovid19patientswithards
AT shettypadmashria furthervalidationoftheefficacyofmesenchymalstemcellinfusionsforreducingmortalityincovid19patientswithards
AT zaniratigabriele furthervalidationoftheefficacyofmesenchymalstemcellinfusionsforreducingmortalityincovid19patientswithards
AT jinkunlin furthervalidationoftheefficacyofmesenchymalstemcellinfusionsforreducingmortalityincovid19patientswithards

Ejemplares similares